Watch for announcement of a new European commercialization partner for D-PLEX, which could include an upfront payment and milestone structure. The regained rights also increase the asset's attractiveness ahead of potential FDA/EMA decisions.
Price Chart
Executive Summary
PolyPid regained exclusive European commercialization rights for D-PLEX after mutually terminating its 2022 license agreement with ADVANZ PHARMA. The company now controls global rights to D-PLEX, which recently completed a Phase 3 trial and has NDA submissions with both the FDA and EMA, as well as a North American partnership with Azurity Pharmaceuticals. This increases strategic flexibility for a potential European partnership with a larger pharmaceutical company.
Key Facts
- PolyPid and ADVANZ PHARMA mutually terminated the exclusive License, Distribution and Supply Agreement for D-PLEX in Europe dated August 2, 2022.
- European commercialization rights for D-PLEX have reverted to PolyPid.
- PolyPid completed the Phase 3 SHIELD II trial, submitted an NDA to the FDA, submitted to the EMA, and established a North American partnership with Azurity Pharmaceuticals.
- CEO stated the company believes D-PLEX is a highly attractive opportunity for multinational pharmaceutical companies in Europe and other large markets.
Financial Impact
No financial terms disclosed; regaining rights eliminates any future milestone or royalty obligations to ADVANZ PHARMA and positions PolyPid to negotiate a new European partnership directly.
Risk Factors
- No new European partner is guaranteed; PolyPid may need to commercialize D-PLEX in Europe independently, requiring significant capital and infrastructure.
- Regulatory approval from FDA and EMA is not assured; negative decisions would materially impair D-PLEX's commercial prospects.
- The termination may have included a settlement or payment obligation not disclosed in the filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-105474 |
| Document: ea030731501ex99-1.htm | 0001213900-26-105474 |
| Document: 0001213900-26-105474-index-headers.html | 0001213900-26-105474 |
| Document: 0001213900-26-105474-index.html | 0001213900-26-105474 |
| Document: 0001213900-26-105474.txt | 0001213900-26-105474 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $4.90 | awaiting T+60 | — | $5.29 (+7.96%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Aug 12, 2026 10w ago | 6-K | $4.78 | awaiting T+60 | — | $5.29 (+10.67%) |
Aug 12, 2026 10w ago | 6-K | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Aug 12, 2026 10w ago | Press Release | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Jul 29, 2026 12w ago | 6-K | $4.08 $5.13 | ▲ +25.74% | ▲ +21.01% | $5.29 (+29.66%) |
Jul 21, 2026 13w ago | 6-K | $3.74 $4.83 | ▲ +29.14% | ▲ +26.30% | $5.29 (+41.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers